bismuth + cefuroxime + doxycycline + rabeprazole

This drug combination is a bismuth-containing quadruple therapy (BQT) regimen specifically investigated for the eradication of *Helicobacter pylori* infection. It consists of four distinct pharmacological agents: rabeprazole, a proton pump inhibitor (PPI) that suppresses gastric acid secretion to enhance antibiotic stability and efficacy; bismuth (typically as bismuth potassium citrate), which exerts direct bactericidal effects and provides mucosal protection; cefuroxime, a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis; and doxycycline, a tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. This specific combination has been evaluated as a first-line or rescue therapy, particularly in regions with high resistance to standard antibiotics like clarithromycin and metronidazole. Clinical research on this regimen has been notably conducted by investigators at The First Affiliated Hospital of Ningbo University.

Other names

BCDR regimenrabeprazole-bismuth-cefuroxime-doxycycline